SOTAC PHARMACEUTICALS
|
|
BOM :      NSE : SOTAC     | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : NA |
Dec 05,2024 |
Price(EOD): ₹ 110.70
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 121.77 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
SOTAC PHARMACEUTICALS | -3.7% | -15.3% | -16.9% |
SUN PHARMACEUTICAL INDUSTRIES | 1.6% | 0.1% | 46.2% |
CIPLA | -2.3% | -5.4% | 24.4% |
DR REDDYS LABORATORIES | 3.2% | -2.2% | 5.8% |
ZYDUS LIFESCIENCES | 1.3% | -2.6% | 51.8% |
DIVIS LABORATORIES | -1.2% | 3.4% | 65% |
MANKIND PHARMA | 2.2% | -4.2% | 35.5% |
TORRENT PHARMACEUTICALS | 1.1% | 5.1% | 55.7% |
LUPIN | 3.7% | -2.9% | 62.1% |
FUNDAMENTAL ANALYSIS OF SOTAC PHARMACEUTICALS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF SOTAC PHARMACEUTICALS
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
32.34
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 3.78 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] 2.7
P/B Calculated based on Book Value of Rs 45.26 Cr
[Latest Year - Mar2024 - Consolidated Results ] 1.28
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 95.61 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
296% 465% - |
SHARE PRICE MOMENTUM OF SOTAC PHARMACEUTICALS
SOTAC PHARMACEUTICALS vs SENSEX
DEBT OF SOTAC PHARMACEUTICALS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.23 0.93 1.04 0.73 |
0.55 2.21 1.12 1.29 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF SOTAC PHARMACEUTICALS
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF SOTAC PHARMACEUTICALS
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-1.93% -24.07% -11.8% 53.65% |
27.07% 15.48% 9.06% 150.65% |
QtrlyTrend |
2 | |
Latest Qtr: Jun2024 | ||
Quarterly Result Analysis → |
SOTAC PHARMACEUTICALS related INDICES
You may also like the below Video Courses
FAQ about SOTAC PHARMACEUTICALS
Is SOTAC PHARMACEUTICALS good for long term investment?
As on Dec 05,2024, the Fundamentals of SOTAC PHARMACEUTICALS look Poor and hence it may not be good for long term investment ! See Financial Performance of SOTAC PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is SOTAC PHARMACEUTICALS UnderValued or OverValued?
As on Dec 05,2024, SOTAC PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of SOTAC PHARMACEUTICALS ?
As on Dec 05,2024, the Intrinsic Value of SOTAC PHARMACEUTICALS is Rs. 23.77 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 27.93
Fair Value [Median EV / Sales Model] : Rs. 19.60
Fair Value [Median Price / Sales Model] : Rs. 0.00
Estimated Median Fair Value of SOTAC PHARMACEUTICALS : Rs. 23.77
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.